Safety Study of Flavocoxid in Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Objective of this study is to evaluate safety and tolerability of flavocoxid administered at
the daily oral dose of 500 or 1000 mg/die for one year in DMD patients, alone or in
association with steroids (deflazacort on alternate days) started at least one year before.
The investigators will also perform a multidimensional clinical evaluation covering
functional and muscle strength and quality of life (QoL)assessments.